An evaluation of interleukin genes fails to identify clear susceptibility loci for multiple sclerosis

Journal of the Neurological Sciences

Volumn 176, Issue 1, 2000, Pages 4-12

  McDonnell, G V ^a   Kirk, C W ^b   Hawkins, S A ^a,b   Graham, C A ^c  

^a ROYAL VICTORIA HOSPITAL   (United Kingdom)

^b ROYAL GROUP OF HOSPITALS TRUST   (United Kingdom)

^c QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Association studies; Cytokines; Genes; Interleukins; Microsatellites; Multiple sclerosis; Primary progressive

Indexed keywords

CYTOKINE; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 4; INTERLEUKIN 9;

ARTICLE; CONTROLLED STUDY; GENE CONTROL; GENE FREQUENCY; GENE LOCUS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ALLELES; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; DNA; FEMALE; FLUORESCENT DYES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTERLEUKINS; MALE; MICROSATELLITE REPEATS; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC;

EID: 0034194562     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-510X(00)00291-4     Document Type: Article

References (62)

1. Cavender D.E., Haskard D.O., Joseph B., Ziff M. Interleukin-1 increases the binding of human B and T lymphocytes to endothelial cell monolayers. J Immunol. 136:1986;203-206.
2. Matsuda M., Tsukada N., Miyagi K., Yanagisawa N. Increased interleukin-1 production by peripheral blood mononuclear cells in patients with multiple sclerosis. J. Neurol Sci. 102:1991;100-104.
3. Tsukada N., Matsuda M., Miyagi K., Yanagisawa N. Cytotoxicity of T cells for cerebral endothelium in multiple sclerosis. J. Neurol Sci. 117:1993;140-147.
4. Rubin L.A., Nelson D.L. The soluble interleukin-2 receptor: biology, function and clinical application. Ann. Intern. Med. 113:1990;619-627.
5. Campen D.H., Horwitz D.A., Quismorio F.P. Jr, Ehresmann G.R., Martin W.J. Serum levels of interleukin-2 receptor and activity of rheumatic diseases characterised by immune system activation. Arthritis Rheum. 31:1988;1358-1364.
6. Rubin L.A., Snow K.M., Kurman C.C., Nelson D.L., Keystone E.C. Serial levels of soluble interleukin-2 receptor in the peripheral blood of patients with rheumatoid arthritis: correlations with disease activity. J. Rheumatol. 17:1990;597-602.
7. Colvin R.B., Fuller T.C., MacKeen L., Kung P.C., Ip S.H., Cosimi A.B. Plasma interleukin-2 receptor levels in renal allograft recipients. Clin Immunol Immunopathol. 43:1987;273-276.
8. Adams D.H., Wang L., Hubscher S.G., Elias E., Neuberger J.M. Soluble interleukin-2 receptors in serum and bile of liver transplant recipients. Lancet. 1:1989;469-471.
9. Kroemer G., Wick G. The role of interleukin-2 in autoimmunity. Immunol Today. 10:1989;246-251.
10. Hartung H.-P., Hughes R.A.C., Taylor W.A., Heiinger K., Reiners K., Toyka K.V. T cell activation in Guillain-Barré syndrome and in MS: elevated serum levels of soluble IL-2 receptors. Neurology. 40:1990;215-218.
11. Gallo P., Piccino M.G., Tavolato B., Sidén A. A longitudinal study of IL-2, sIL-2R, IL-4 and WN-gamma in multiple sclerosis CSF and serum. J Neurol. Sci. 101:1991;227-232.
12. Peter J.B., Boctor F.N., Tourtellote W.W. Serum and CSF levels of IL-2, sIL-2R, TNF-α, and IL-1β in chronic progressive multiple sclerosis: expected lack of clinical utility. Neurology. 41:1991;121-123.
13. Chalon M.P., Sindic C.J.M., Laterre E.C. Serum and CSF levels of soluble interleukin-2 receptors in MS and other neurological diseases: a reappraisal. Acta Neurol Scand. 87:1993;77-82.
14. Adachi K., Kumamoto T., Araki S. Elevated soluble interleukin-2 receptor levels in patients with active multiple sclerosis. Ann. Neurol. 28:1990;687-691.
15. Capra R., Mattioli F., Marciano N., Vignolo L.A., Bettinzioli M., Alro P., et al. Significantly higher levels of soluble interleukin-2 in patients with relapsing-remitting multiple sclerosis compared with healthy subjects. Arch Neurol. 47:1990;254.
16. Bansil S., Troiano R., Cook S.D., Rohowsky-Kochan C. Serum soluble interleukin-2 receptor levels in chronic progressive, stable and steroid-treated multiple sclerosis. Acta Neurol Scand. 84:1991;282-285.
17. Greenberg S.I., Marcon L., Hurwitz B.I., Waldman T.A., Nelson D.L. Elevated levels of soluble interleukin-2 receptors in multiple sclerosis. New Engl J Med. 319:1988;1019-1020.
18. Peleman R., Wu I., Fargeas C., Delespesse G. Recombinant interleukin 4 suppresses the production of interferon gamma by human mononuclear cells. J Exp Med. 170:1989;1751-1756.
19. Street N.E., Mosmann T.R. Functional diversity of T lymphocytes due to secretion of different cytokine patterns. FASEB J. 5:1991;171-177.
20. Racke M.I.K., Bonomo A., Scott D.E., Cannella B., Levine A., Raine C.S., et al. Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease. J Exp Med. 180:1994;1961-1966.
21. Kuchroo V.K., Das M.I.P., Brown I.A., Ranger A.M., Zamvil S.S., Sobel R.A., et al. B7-l and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell. 80:1995;707-718.
22. Lu C.-Z., Jensen M.A., Arnason B.G.W. Interferon gamma and interleukin-4-secreting cells in multiple sclerosis. J Neuroimmunol. 46:1993;123-128.
23. Uyttenhove C., Simpson R., Van Snick I. Functional and structural characterization of P40, a mouse glycoprotein with T cell growth factor activity. Proc Natl Acad Sci USA. 85:1988;6934.
24. Gessner A., Blum H., Rollinghoff M. Differential regulation of IL-9 expression after infection with Leishmania major in susceptible and resistant mice. Immunobiology. 1989:1993;419.
25. Renauld I.-C., Vink A., Louahed I., Van Snick I. Interleukin-9 is a major anti-apoptotic factor for thymic lymphomas. Blood. 85:1995;1300-1305.
26. Fiorentino D.F., Zlotnik A., Vieira P., Mosmann T.R., Howard M., Moore K.W., et al. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol. 146:1991;3444-3451.
27. Moore K.W., O'Garra A., de Waal Malefyt R., Vieira P., Mosmann T.R. Interleukin-10. Annu Rev Immunol. 11:1993;165-190.
28. Wanidworanun C., Strober W. Predominant role of tumor necrosis factor-α in human monocyte IL-10 synthesis. J Immunol. 151:1993;6853-6861.
29. Rieckmann P., Albrecht M., Kitze B., Weber T., Tumani H., Broocks A., et al. Cytokine mRNA levels in mononuclear blood cells from patients with multiple sclerosis. Neurology. 44:1994;1523-1526.
30. Porrii A.M., Gambi D., Reder A.T. Interferon effects on interleukin-10 secretion. Mononuclear cell response to interleukin-10 is normal in multiple sclerosis patients. J Neuroimmunol. 61:1995;27-34.
31. Rudick R.A., Ransohoff R.M., Peppler R., VanderBrug Medendorp S., Lehmann P., Alam I. Interferon beta induces interleukin-10 expression: relevance to multiple sclerosis. Ann Neurol. 40:1996;618-627.
32. Rott O., Fleischer B., Cash E. Interleukin-10 prevents experimental allergic encephalomyelitis in rats. Eur J Immunol. 24:1994;1434-1440.
33. McDonnell G.V., Hawkins S.A. Clinical study of primary progressive multiple sclerosis in Northern Ireland. J Neurol Neurosurg Psychiatry. 64:1998;451-454.
34. Thompson A.J., Kermode A.G., MacManus D.G., Kendall B.E., Kingsley D.P.E., Moseley I.F., et al. Patterns of disease activity in multiple sclerosis: clinical and magnetic resonance imaging study. Br Med J. 300:1990;631-634.
35. Thompson A.J., Kermode A.G., Wicks D., MacManus D.G., Kendall B.E., Kingsley D.P.E., et al. Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol. 29:1991;53-62.
36. Revesz T., Kidd D., Thompson A.J., Barnard R.O., McDonald W.I. A comparison of the pathology of primary and secondary progressive multiple sclerosis. Brain. 117:1994;759-765.
37. Giovannoni G., Thorpe J.W., Kidd D., Kendall B.E., Moseley I.F., Thompson A.J., et al. Soluble E-selectin in multiple sclerosis: raised concentrations in patients with primary progressive disease. J Neurol Neurosurg Psychiatry. 60:1996;20-26.
38. McDonnell G.V., McMillan S.A., Douglas I.P., Droogan A.G., Hawkins S.A. Raised CSF levels of soluble adhesion molecules across the clinical spectrum of multiple sclerosis. J Neuroimmunol. 85:1998;186-192.
39. Olerup O., Hillert J., Fredrikson S., Olsson T., Kam-Hansen S., Möller E., et al. Primarily chronic progressive and relapsing/remitting multiple sclerosis: two immunogenetically distinct disease entities. Proc Natl Acad Sci USA. 86:1989;7113-7117.
40. Hillert J., Grönning M., Nyland H., Link H., Olerup O. An immunogenetic heterogeneity in multiple sclerosis. J Neurol Neurosurg Psychiatry. 55:1992;887-890.
41. Weinshenker B.G., Santrach P., Bissonet A.S., McDonnell S.K., Schaid D., Moore S.B., et al. Major histocompatibility complex class II alleles and the course and outcome of MS. Neurology. 51:1998;742-747.
42. Poser C.M., Paty D.W., Scheinberg L., McDonald W.I., Davis F.A., Ebers G.C., et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 13:1983;227-231.
43. Lublin F.D., Reingold S.C. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology. 46:1996;907-911.
44. Furutani Y., Notake M., Fukui T., Ohue M., Nomura H., Yamada M., et al. Nucleic Acids Res. 14:1986;3167-3179.
45. Modi W.S., Masuda A., Yatnada M., Oppenheim I.I., Matushima K., O'Brien S.I. Chromosomal localization of the human interleukin 1α (IL-1α) gene. Genomics. 12:1988;310-314.
46. Lafage M., Maroc N., Dubreuil P., de Waal Malefijt R., Pébusque M.-J., Carcassonne Y., et al. The human interleukin-1α gene is located on the long arm of chromosome 2 at band q13. Blood. 73:1989;104-107.
47. Epplen C., Frank G., Gomolka M., Albert E., Nurnberg P., Epplen J.T. Dinucleotide repeat polymorphism in the human IL1A gene. Hum Mol Genet. 3:1994;1710.
48. Epplen C., Frank G., Gomolka M., Nagy M., Nurnberg P., Epplen J.T. Dinucleotide repeat polymorphism in the IL2 and IL5RA genes. Hum Mol Genet. 3:1994;679.
49. Gnarra J.R., Otani H., Wang M.G., McBride O.W., Sharon M., Leonard W. Human interleukin-2 receptor β-chain gene: chromosomal localization and identification of 5′ regulatory sequences. Proc Natl Acad Sci USA. 87:1990;3440-3444.
50. van Leeuwen B.H., Martinson M.E., Webb G.C., Young I.G. Molecular organisation of the cytokine gene cluster, involving the human IL-3, IL-4, IL-5, and GM-CSF genes, on human chromosome 5. Blood. 73:1989;1142-1148.
51. Le Beau M.M., Lemons R.S., Espinosa R., Larson R.A., Arai N., Rowley J.D. Interleukin-4 and interleukin-5 map to human chromosome 5 in a region encoding growth factors and receptors and are deleted in myeloid leukaemias with a del(5q). Blood. 73:1989;647-650.
52. Modi W.S., Pollock D.D., Mock B.A., Banner C., Renauld J.-C., Van Snick J. Regional localization of the human glutaminase (GLS) and interleukin-9 (IL9) genes by in situ hybridization. Cytogenet Cell Genet. 57:1991;114-116.
53. Saltman D.L., Dolganov G.M., Warrington I.A., Wasmuth J.J., Lovett M. A physical map of 15 loci on human chromosome 5q23-q33 by two-color fluorescence in situ hybridization. Genomics. 16:1993;726-732.
54. Kube D., Platzer C., von Knethen A., Straub H., Bohien H., Hafner M., et al. Isolation of the human interleukin- promoter. Characterisation of the promoter activity in Burkitt's lymphoma cell lines. Cytokine. 7:1995;1-7.
55. Eskdale J., Gallagher G. A polymorphic dinucleotide repeat in the human IL-10 promoter. Immunogenetics. 42:1995;444-445.
56. Crusius J.B.A., Pefia A.S., van Oosten B.W., Bioque G., Garcia A., Dijkstra C.D., et al. Interleukin-1 receptor antagonist gene polymorphism and multiple sclerosis. Lancet. 346:1995;979-990.
57. Semana G., Yaouanq J., Alizadeh M., Clanet M., Edan G. Interleukin-1 receptor antagonist gene in multiple sclerosis. Lancet. 349:1997;476.
58. Huang W.-X., He B., Hillert J. An interleukin 1-receptor-antagonist gene polymorphism is not associated with multiple sclerosis. J Neuroimmunol. 67:1996;143-144.
59. Epplen C., Jäckel S., Santos E.J.M., D'Souza M., Poehiau D., Dotzauer B., et al. Genetic predisposition to multiple sclerosis as revealed by immunoprinting. Ann Neurol. 41:1997;341-352.
60. Sciacca F.L., Fern C., Vandenbroeck K., Veglia F., Gobbi C., Martinelli F., et al. Relevance of interleukin-1 receptor antagonist intron-2 polymorphism in Italian MS patients. Neurology. 52:1999;1896-1898.
61. Marsh D.G., Neely J.D., Breazeale D.R., Ghosh B., Freidhoff L.R., Ehrlich-Kautzky E., et al. Linkage analysis of IL4 and other chromosome 5q31.1 markers and total serum immunoglobulin E concentrations. Science. 264:1994;1152-1156.
62. Vandenbroeck K., Martino G., Marrosu M.G., Consiglio A., Zaffaroni M., Vaccargiu S. Occurrence and clinical relevance of an interleukin-4 gene polymorphism in patients with multiple sclerosis. J Neuroimmunol. 76:1997;189-192.